HMH Maestro
  • Action Center
  • Topics
  • On-Call Schedules
  • CME
  • Helpful Tools
Open main menu
  • Action Center
  • Topics
  • On-Call Schedules
  • CME
  • Helpful Tools
  • Topics
  • Featured Specialties
  • Hackensack University Medical Center Enrolling Patients in Alzheimer and Dementia Trials

Hackensack University Medical Center Enrolling Patients in Alzheimer and Dementia Trials

Updated:
November 9, 2023
Published:
June 29, 2022

Hackensack University Medical Center is enrolling in three clinical trials. If you have a patient who is a fit, email Dr. Manisha Parulekar or call the research coordinator at 551-996-5565.

New IDEAS Study

The New IDEAS study examines if amyloid positron emission tomography (PET) is a useful tool to guide decision-making in the management of patients with mild cognitive impairment or dementia of uncertain etiology.

Amyloid PET detects amyloid plaques in the brain, a core neuropathological feature of Alzheimer’s disease. The new Imaging Dementia—Evidence for Amyloid Scanning (New IDEAS) Study will follow up on results from the original IDEAS study to assess the value of brain PET scans in diagnosing and managing Alzheimer’s disease. Get more information.

S-Citab Clinical Trial

Hackensack University Medical Center’s Center for Memory Loss and Brain Health is enrolling patients in the multicenter S-Citad clinical trial to study the safety and efficacy of Escitalopram, an antidepressant, for the treatment of agitation related to Alzheimer’s disease. This study is sponsored by the National Institute on Aging.

Patients may be eligible for the study if they have received a diagnosis of Alzheimer’s disease, and experience frequent agitation or aggression. The study will last approximately six months. Patients will be randomized to receive either the study drug (escitalopram) or placebo (an inactive substance) in pill form. Get more information.

ATH-1017 Clinical Trial

The physicians at Hackensack University Medical Center and the Center for Memory Loss & Brain Health are conducting a clinical trial that may have big implications for patients and families impacted by Alzheimer’s disease. Investigators have started enrollment in a clinical trial for ATH-1017, an investigational medication for the treatment of mild to moderate Alzheimer’s disease.

According to clinical trial sponsor Athira Pharma, ATH-1017 enhances the HGF/MET system, one of the brain’s repair mechanisms. Enhancing HGF/MET signaling may improve brain activity, repair brain connections, reduce stress and inflammation, and rescue brain cells, which may lead to rapid recovery of memory and function. Get more information.

  1. Clinical Alerts
  2. Featured Physicians
  3. Featured Specialties
  4. HMH Partners Updates
  5. Hospitals and Locations
  6. IT Alerts
  7. Leadership Announcements
  8. Legal and Regulatory
  9. Payor Updates
  10. Physician Tips
  11. Quality and Safety
  • Topics
  • Featured Specialties
  • Hackensack University Medical Center Enrolling Patients in Alzheimer and Dementia Trials

About HMH Maestro

  • Accessibility Statement
  • Careers

Information

  • Visitors/Guests
  • Patients

Privacy Policy|Terms & Conditions
© 2026
Hackensack Meridian Health, Inc.